New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033, growing at a ...

This study means that clinicians should use the AASLD/IDSA simplified treatment recommendation for FIB-4 for staging liver fibrosis “and identify those with advanced hepatic fibrosis/cirrhosis ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- The global ????? ????? ????? ????? is set to witness significant expansion over the coming decade ...

offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire / -- The global liver fibrosis treatment market is set to witness significant expansion over the coming decade, with revenues anticipated ...

New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033, growing at a ...